Valeant Pharmaceuticals' Bausch + Lomb Gets U.S. FDA Clearance for Novel Monthly Disposable Contact Lens

Valeant Pharmaceuticals International, Inc. and Bausch + Lomb announced that the U.S. Food and Drug Administration (FDA) has issued marketing clearance for Bausch + Lomb's newest frequent replacement silicone hydrogel contact lenses made with MoistureSeal Technology.

According to a release, this novel technology combines a new material with new manufacturing processes to produce a contact lens that offers comfort and vision.

"We are encouraged to receive this significant marketing clearance much sooner than originally expected," stated J. Michael Pearson, chairman and chief executive officer of Valeant. "When paired with Biotrue ONEday our premium daily disposable contact lenses launched last year we believe this new technology will begin to build an improved contact lens business by providing contact lens wearers with unsurpassed comfort and vision throughout the day."

MoistureSeal Technology is the latest vision care development from Bausch + Lomb building on the track record of developments including Biotrue ONEday contact lenses and Biotrue Multi-Purpose Solution.

Bausch + Lomb's frequent replacement silicone hydrogel contact lens is only available with a prescription from an eye care professional.

Valeant Pharmaceuticals International, Inc. is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, eye health, neurology, and branded generics.

Bausch + Lomb is a company focusing in contact lenses and lens care products, ophthalmic surgical devices and instruments, and ophthalmic pharmaceuticals.

More Information:

((Comments on this story may be sent to